These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 32169687)
1. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies. Hewison A; Atkin K; McCaughan D; Roman E; Smith A; Smith G; Howell D Eur J Oncol Nurs; 2020 Apr; 45():101730. PubMed ID: 32169687 [TBL] [Abstract][Full Text] [Related]
2. Medication experience and patient's related needs in chronic myeloid leukemia treated with tyrosine kinase inhibitors: Systematic review. Cachafeiro Pin AI; Villaverde Piñeiro L; Martín Clavo S; Silva Castro MM Farm Hosp; 2023; 47(2):85-92. PubMed ID: 36599752 [TBL] [Abstract][Full Text] [Related]
3. [Translated article] The needs and medication experience of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A systematic review. Cachafeiro Pin AI; Villaverde Piñeiro L; Martín Clavo S; Silva Castro MM Farm Hosp; 2023; 47(2):T85-T92. PubMed ID: 36870818 [TBL] [Abstract][Full Text] [Related]
4. The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach. Guilhot F; Coombs J; Szczudlo T; Zernovak O; Paolantonio M; Bender C; Macdonald NJ; Shapiro A Patient; 2013; 6(2):81-92. PubMed ID: 23529848 [TBL] [Abstract][Full Text] [Related]
6. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243 [TBL] [Abstract][Full Text] [Related]
7. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. Chen LC; Chen TC; Huang YB; Chang CS Int J Clin Pharm; 2014 Feb; 36(1):120-7. PubMed ID: 24154825 [TBL] [Abstract][Full Text] [Related]
8. Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study. Kekäle M; Söderlund T; Koskenvesa P; Talvensaari K; Airaksinen M J Adv Nurs; 2016 Sep; 72(9):2196-206. PubMed ID: 27113362 [TBL] [Abstract][Full Text] [Related]
9. Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors. Hefner J; Csef EJ; Kunzmann V Oncol Nurs Forum; 2017 Nov; 44(6):E232-E240. PubMed ID: 29052661 [TBL] [Abstract][Full Text] [Related]
10. Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trial. Djodikromo MF; Hermens RP; Bemt BJVD; Smit Y; Govers TM; Bekker CL; Blijlevens NM BMC Cancer; 2023 Mar; 23(1):231. PubMed ID: 36899295 [TBL] [Abstract][Full Text] [Related]
11. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study. Wu S; Chee D; Ugalde A; Butow P; Seymour J; Schofield P Palliat Support Care; 2015 Apr; 13(2):255-63. PubMed ID: 24524212 [TBL] [Abstract][Full Text] [Related]
12. Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia. Hosoya K; Mochinaga S; Emoto A; Yokoo H; Tokushima H; Egoshi M; Sueoka-Aragane N; Kimura S Int J Clin Oncol; 2015 Dec; 20(6):1203-10. PubMed ID: 26002407 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial. Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798 [TBL] [Abstract][Full Text] [Related]
15. Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review. Heiney SP; Sorrell M; Sheng J; Adams SA; Nelson K; Nguyen LA; Edwards A; Wickersham KE Am J Clin Oncol; 2021 Jun; 44(6):291-298. PubMed ID: 33867480 [TBL] [Abstract][Full Text] [Related]
16. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Cuellar S; Vozniak M; Rhodes J; Forcello N; Olszta D J Oncol Pharm Pract; 2018 Sep; 24(6):433-452. PubMed ID: 28580869 [TBL] [Abstract][Full Text] [Related]
17. Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital. Lee PM; Chang CT; Yusoff ZM Int J Clin Pharm; 2021 Feb; 43(1):46-54. PubMed ID: 32524510 [TBL] [Abstract][Full Text] [Related]
18. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan. Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021 [TBL] [Abstract][Full Text] [Related]
19. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice. Huguet F; Cayuela JM; Cambier N; Carpentier N; Tindel M; Violet I; Zunic P; Lascaux A; Etienne G; Br J Haematol; 2019 Dec; 187(5):615-626. PubMed ID: 31394591 [TBL] [Abstract][Full Text] [Related]
20. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]